Share:
Peer-Reviewed Publication
J Imaging Inform Med2026March 31, 2026Journal Article

3D deep learning model to predict the recurrence of stage IA invasive lung adenocarcinoma after sub-lobar resection: a multicenter retrospective cohort study.

Xin Fan1, Chen Liang2, Xue-Qin Ma3, Yi-Bo Feng4, Qian-Rui Fan4, Da-Wei Wang4, Tian-You Luo1, Fa-Jin Lv5, Qi Li6
1Department of Radiology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China.
2Department of Radiology, Second Affiliated Xinqiao Hospital of Army Medical University, No.83 Xinqiao Main Street, Shaping District, Chongqing, China.
3Department of Radiology, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, China.
4Institute of Research, Infervision Medical Technology Co, Ltd, 25 F Building E, Yuanyang International Center, Chaoyang District, Beijing, China.
5Department of Radiology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China. lvfj2020@sina.com.
6Department of Radiology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China. 202770@hospital.cqmu.edu.cn.

Abstract

The purpose of this study was to investigate the efficacy of a three-dimensional (3D) deep learning (DL) model in predicting recurrence risk of stage IA invasive lung adenocarcinoma (ILADC) after sub-lobar resection (SLR). A total of 287 stage IA ILADC patients were assigned to training and internal validation sets (4:1), with an external test cohort of 112 patients from two institutions. Three cl…

Create a free account to keep reading

Free members get 10 full research views every month across publications, clinical trials, FDA clearances, adverse events, and NIH grants. No credit card required.

Want unlimited research access? See Pro plans

Data Accuracy Notice: Research intelligence on Health AI Central is aggregated from public sources (PubMed, ClinicalTrials.gov, FDA, NIH, CMS, and others) and refreshed nightly. Classifications and derived metrics are produced by automated methods described in our Methodology. We recommend verifying critical data points against the primary sources before making decisions.